<DOC>
	<DOCNO>NCT02900430</DOCNO>
	<brief_summary>Patients acute myeloid leukemia ( AML ) risk develop severe infection whose invasive aspergillosis ( IA ) . These infection lead important morbidity mortality . Antifungal prophylaxis recommend posaconazole AML patient neutropenia induced induction chemotherapy . Their application uniform .</brief_summary>
	<brief_title>Invasives Aspergillosis Acute Myeloid Leukemia</brief_title>
	<detailed_description>Invasive aspergillosis frequent infection hematological malignancy particular neutropenia induce chemotherapy . Their incidence range 5 25 % accord literature . Mortality may reach 30 % . Our study describe IA incidence AML patient treat intensive chemotherapy depend antifungal prophylaxis posaconazole . From 2009 2011 , patient receive antifungal prophylaxis . From 2012 2015 , patient receive posaconazole induction salvage chemotherapy . During study period , efficacy posaconazole evaluate accord construction/demolition period hospital . All patient hospitalize High Efficiency Particulate Air ( HEPA ) filtration system .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>&gt; 18 year acute myeloid leukemia intensive chemotherapy ( induction , consolidation , salvage , bone marrow transplantation ) &lt; 18 year pregnancy intensive chemotherapy ( palliative treatment , azacytidine ... )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>